Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

ABSTRACT

A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

KEYWORDS:

• SARS-CoV-2
• receptor-binding domain
• vaccine
• neutralizing antibodies

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent for the Coronavirus Disease 2019 (COVID-19). After the outbreak of COVID-19 in late 2019, a safe, effective and scalable vaccine against the SARS-CoV-2 is in urgent need. Like other coronaviruses, the SARS-CoV-2 spike (S) protein contains two subunits, S1 and S2, and the receptor-binding domain (RBD) is embedded in the S1 subunit.¹ Previous studies on SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) vaccine development indicate that the spike RBD predominantly elicits neutralizing antibodies in animals,^2,3 while antibodies directed outside of the RBD may have no neutralizing capabilities.^2,4 SARS-CoV RBD, but not the entire S protein, induces higher level of neutralizing antibodies to prevent the disease.² Similarly, SARS-CoV RBD fused with IgG constant region (RBD-Fc) also induces a protective humoral response against SARS-CoV.² Furthermore, recombinant MERS-CoV RBD immunization protects the rhesus macaques challenged with live MERS-CoV.⁵ On the other hand, the non-neutralizing antibodies were shown to induce antibody-dependent enhancement (ADE) which can enhance infections caused by heterologous SARS-CoV strains or mediate harmful immune responses.² Considerable evidence has proved that the recombinant RBD-based subunit vaccine is a promising candidate vaccine against the SARS-CoV-2 infection.

To examine the immunogenicity of SARS-CoV-2 RBD, his-tagged recombinant RBD covering the a.a. 333–516 of the S protein was cloned into pSecTag2A expression vector and expressed in-house using the Expi293 mammalian cell expression system (ThermoFisher). Since RBD contains a complex tertiary structure with many intramolecular disulfide bonds, the use of mammalian cells can help express proteins with proper folding and post-transcriptional modifications. In addition, through structural modeling, the selected RBD fragment maintains a complete structure without residues that may cause undesirable immunogenicity. RBD-Fc fusion protein was acquired from Sino Biological (#40592-V05H). Both proteins were confirmed of their purity (>95%) and angiotensin-converting enzyme 2 receptor binding specificity, and they were formulated with alum for vaccination. Groups of C57BL/6 mice were inoculated subcutaneously with 5 μg of RBD-Fc (two doses: day 0 and 21) or RBD (three doses: day 0, 21, 49), and mice receiving PBS were used as controls. To assess the humoral immunity in response to RBD-based antigen immunization, RBD-specific IgG antibody titer was determined by ELISA. The results (Figure 1A) showed that, after the first dose, RBD-Fc vaccination immediately induced a strong RBD-specific IgG titer on day 21, and the second dose slightly boosted the RBD-specific IgG response on day 35; the titer level remained stable until day 63. In contrast, RBD initially elicited subdued RBD-specific humoral response on day 21 as no detectable RBD-specific humoral response was observed in 4 out of the 5 vaccinated mice. The second vaccination of RBD resulted in a significant increase in anti-RBD-specific IgG titer on day 35, and additional immunization on day 49 further boosted the anti-RBD IgG titer on day 63. On day 63, similar levels of RBD-specific IgG titers were observed in the RBD-Fc and RBD groups. In addition, neutralizing antibodies (100% neutralizing titer, NT₁₀₀) were further monitored using the SARS-CoV-2 neutralizing assays in Vero E6 cells and a lentiviral-based SARS-CoV-2 pseudovirus neutralization assay based on luminescence readout. As shown in Figure 1B, after the first immunization, RBD-Fc induced neutralizing titers of 1:40 to 1:160 on day 21. Subsequent booster increased the neutralizing titers to 1:320 and 1:1280 on day 35 and day 63, respectively. For the RBD immunization, the neutralizing responses in mice sera were barely detected on day 21 and 35, however, after the third dose on day 49, significant neutralizing titers were detected, and the titers were ranged between 1:40 and 1:2560 on day 63. PBS-immunized group did not demonstrate any neutralizing titers. The data obtained from the pseudovirus neutralization assays were similar to that performed using SARS-CoV-2 virus, hence validating the vaccine effectiveness.

Figure 1. SARS-CoV-2 RBD induces a strong humoral response in mice. Three groups of mice were vaccinated subcutaneously with PBS, 5 μg RBD-Fc/alum (two doses: day 0 and 21) or 5 μg RBD/alum (three doses: day 0, 21, 49), and serum was collected on day 21, 35 and 63. (A) RBD-specific serum IgG response was determined using ELISA on 100 ng RBD-coated microplates. Data represent means ± SEM (n = 3–5). (B) Neutralizing titers were determined by the live SARS-CoV-2 or pseudotyped SARS-CoV-2. Mouse serum was heat-inactivated (56°C, 30 min) prior to the neutralization assay. For live SARS-CoV-2 neutralizing assay, 2-fold serially diluted serum was mixed with 100 TCID₅₀ of SARS-CoV-2 and then incubated with Vero E6 cells for three days. The serum dilution showing no cytopathic effect was recorded as the 100% neutralizing titer (NT₁₀₀). For pseudotyped virus neutralization, lentivirus that carries the full SARS-CoV-2 spike gene and a defective HIV-1 genome encoding the reporter luciferase was used. Serially diluted serum was incubated with 1000 unit of pseudovirus, then added to hACE2-transfected 293 T cells, and incubated for three days. The luciferase activity was measured using the luminescence microplate reader and converted to neutralizing titers. Lines represent means (n = 3–5)

These results indicate that SARS-CoV-2 RBD is a promising candidate for vaccine development. Comparing with the slower and more variable responses observed in the RBD-immunized group, the fusion of the Fc region and RBD largely improves the immunogenicity. One dose of RBD-Fc protein in mice induced a robust antibody response with neutralizing capability against the SARS-CoV-2 (NT₁₀₀: 1:40 to 1:160), the neutralizing titer is comparable with the recommended titer (1:80 to 1:160) of SARS-CoV-2 therapeutic plasma transfusion.^6,7 Thus far, an mRNA-based vaccine that encodes the full-length S protein and adenovirus-based vaccine or DNA-based vaccine expressing full-length S protein are under clinical investigation, and they have reportedly induced moderate neutralizing antibodies against SARS-CoV-2.⁸ However, these full S protein-based vaccine approaches possess risks of ADE manifestation when the SARS-CoV-2 establishes infections in the vaccine recipients.⁴ On the other hand, scalability and stability of RBD subunit production are advantages of RBD-based vaccines.⁹ Although there is no available Fc fusion protein-based vaccine, therapeutic Fc fusion protein drugs have been approved with tolerable safety profile.¹⁰ In this study, we report that recombinant SARS-CoV-2 RBD is able to elicit potent antibody response with neutralizing capability, and its further development is warranted.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Alex Ma in Genomics Research Center, Academia Sinica for providing the cDNA.

Additional information

Funding

This study was supported by the Ministry of Science and Technology (MOST-109-3114-Y-001-001 and MOST-109-2327-B-002-009), National Taiwan University and Academia Sinica, Taiwan.